CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.
You may also be interested in...
Woodcock's Legacy: CDER Organizational Improvements
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
CBER Approvals Hit A High Note For Director Midthun's Swan Song
Twelve novel biologics in 2015 sets record, with 'biobetter' coagulation factors again making up largest group of new products.
People In The News: CEO Post Changes Hands At Express Scripts, Xenoport, Promethera, Molecular Response, Protagonist
NACDS and USP also bring on new execs; more personnel changes in this month's column.